Trehalose suppresses antibody aggregation during the culture of Chinese hamster ovary cells. 2014

Masayoshi Onitsuka, and Miki Tatsuzawa, and Ryutaro Asano, and Izumi Kumagai, and Akihiro Shirai, and Hideaki Maseda, and Takeshi Omasa
Institute of Technology and Science, The University of Tokushima, Minamijosanjima-cho 2-1, Tokushima 770-8506, Japan. Electronic address: onitsuka@bio.tokushima-u.ac.jp.

The aggregation of therapeutic antibodies during the manufacturing process is problematic because of the potential risks posed by the aggregates, such as an unexpected immune response. One of the hallmark effects of trehalose, a disaccharide consisting of two alpha-glucose units, is as a chemical chaperone with anti-aggregation activity. In this study, Chinese hamster ovary (CHO) cell line producing a diabody-type bispecific antibody were cultured in medium containing trehalose and the aggregation of the secreted proteins during the culture process was analyzed. An analysis of the various forms of the antibody (monomeric, dimeric, and large aggregates) showed that trehalose decreased the relative content of large aggregates by two thirds. The aggregation kinetics indicated that trehalose directly inhibited the polymerization and aggregation steps in a nucleation-dependent aggregation mechanism. Moreover, both specific and volumetric antibody production were increased in CHO cells cultured in trehalose-containing medium. Thus, the addition of trehalose to recombinant CHO cell cultures would offer a practical strategy for quality improvement in the production of therapeutic antibodies.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D003470 Culture Media Any liquid or solid preparation made specifically for the growth, storage, or transport of microorganisms or other types of cells. The variety of media that exist allow for the culturing of specific microorganisms and cell types, such as differential media, selective media, test media, and defined media. Solid media consist of liquid media that have been solidified with an agent such as AGAR or GELATIN. Media, Culture
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014199 Trehalose
D016466 CHO Cells CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells. CHO Cell,Cell, CHO,Cells, CHO
D018033 Antibodies, Bispecific Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors. Bifunctional Antibodies,Bispecific Antibodies,Bispecific Monoclonal Antibodies,Antibodies, Bifunctional,Antibodies, Bispecific Monoclonal,Monoclonal Antibodies, Bispecific
D019149 Bioreactors Tools or devices for generating products using the synthetic or chemical conversion capacity of a biological system. They can be classical fermentors, cell culture perfusion systems, or enzyme bioreactors. For production of proteins or enzymes, recombinant microorganisms such as bacteria, mammalian cells, or insect or plant cells are usually chosen. Fermentors,Bioreactor,Fermentor

Related Publications

Masayoshi Onitsuka, and Miki Tatsuzawa, and Ryutaro Asano, and Izumi Kumagai, and Akihiro Shirai, and Hideaki Maseda, and Takeshi Omasa
February 2024, Biotechnology progress,
Masayoshi Onitsuka, and Miki Tatsuzawa, and Ryutaro Asano, and Izumi Kumagai, and Akihiro Shirai, and Hideaki Maseda, and Takeshi Omasa
June 2022, Journal of visualized experiments : JoVE,
Masayoshi Onitsuka, and Miki Tatsuzawa, and Ryutaro Asano, and Izumi Kumagai, and Akihiro Shirai, and Hideaki Maseda, and Takeshi Omasa
August 1980, Cryobiology,
Masayoshi Onitsuka, and Miki Tatsuzawa, and Ryutaro Asano, and Izumi Kumagai, and Akihiro Shirai, and Hideaki Maseda, and Takeshi Omasa
May 2014, Journal of bioscience and bioengineering,
Masayoshi Onitsuka, and Miki Tatsuzawa, and Ryutaro Asano, and Izumi Kumagai, and Akihiro Shirai, and Hideaki Maseda, and Takeshi Omasa
May 2018, Biotechnology and bioengineering,
Masayoshi Onitsuka, and Miki Tatsuzawa, and Ryutaro Asano, and Izumi Kumagai, and Akihiro Shirai, and Hideaki Maseda, and Takeshi Omasa
April 1994, American biotechnology laboratory,
Masayoshi Onitsuka, and Miki Tatsuzawa, and Ryutaro Asano, and Izumi Kumagai, and Akihiro Shirai, and Hideaki Maseda, and Takeshi Omasa
November 2022, Critical reviews in biotechnology,
Masayoshi Onitsuka, and Miki Tatsuzawa, and Ryutaro Asano, and Izumi Kumagai, and Akihiro Shirai, and Hideaki Maseda, and Takeshi Omasa
November 1985, Experimental cell research,
Masayoshi Onitsuka, and Miki Tatsuzawa, and Ryutaro Asano, and Izumi Kumagai, and Akihiro Shirai, and Hideaki Maseda, and Takeshi Omasa
January 1987, Methods in enzymology,
Masayoshi Onitsuka, and Miki Tatsuzawa, and Ryutaro Asano, and Izumi Kumagai, and Akihiro Shirai, and Hideaki Maseda, and Takeshi Omasa
January 2005, Biotechnology progress,
Copied contents to your clipboard!